 |
|
|
| |
Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: Results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Tram T. Tran1, Darshan Mehta2,3, Andrea Goldstein3, Eric Cohen3, Yanjun Bao3, Yuri Sanchez Gonzalez31Cedars-Sinai Medical Center, Los Angeles, CA, United States; 2Schaeffer Center for Health Policy and Economics, University of Southern California, CA, United States; 3AbbVie Inc., North Chicago, IL, United States
EASL: Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. ANRS CO12 CirVir Cohort - (04/26/17)
EASL: THERAPY WITH DIRECT ANTIVIRAL AGENTS IN PATIENTS WITH HCV-RELATED LYMPHOPROLIFERATIVE DISORDERS AND MIXED CRYOGLOBULINEMIA - (04/26/17)
|
| |
|
|
|
|
|
